Bicalutamide for Prostate Cancer: How It Works and Sexual Side Effects

Bicalutamide competitively blocks the androgen receptor (AR), preventing testosterone and DHT from stimulating prostate cancer cell growth. It does not lower testosterone — serum levels remain normal or elevated. This preserves more sexual function than LHRH agonists that suppress testosterone to castrate levels. It is used as a flare-prevention agent at LHRH agonist initiation (50mg) or as monotherapy (150mg) for locally advanced non-metastatic prostate cancer in selected men.

Probably less than with LHRH agonists, but it can still happen. Bicalutamide blocks the androgen receptor while serum testosterone is maintained. In randomized studies comparing bicalutamide 150 mg monotherapy with castration, sexual interest and physical capacity were better preserved [2][3]. Gynecomastia and breast pain are the most common side effects [1][3].

Bicalutamide blocks the androgen receptor without lowering testosterone; leuprolide (LHRH agonist) suppresses testosterone to castrate levels (<50 ng/dL). Sexual side effects are significantly worse with leuprolide (profound ED, loss of libido, hot flashes, bone loss, metabolic syndrome) vs. bicalutamide (partial sexual preservation, gynecomastia). For locally advanced prostate cancer, bicalutamide monotherapy offers comparable efficacy with better quality of life — but in most current practice, LHRH agonists with newer AR inhibitors are standard for high-risk or metastatic disease.

Not with certainty, but risk is significantly reduced with prophylactic breast irradiation or tamoxifen started before or early in treatment — neither eliminates the risk completely, but both meaningfully lower the incidence and severity compared to no preventive measure, which is why this conversation is worth having with an oncologist before starting bicalutamide rather than after gynecomastia has already developed.

Yes — bicalutamide is sometimes used off-label in transgender medicine as part of feminizing hormone therapy, given its androgen receptor blocking mechanism, though this is a distinct clinical context from prostate cancer treatment and involves different dosing and monitoring considerations outside the scope of this guide.

Yes — liver function tests are typically monitored periodically given a small risk of hepatotoxicity associated with bicalutamide, alongside routine PSA monitoring to track cancer response and periodic assessment for gynecomastia or other side effects. This monitoring schedule is set by the prescribing oncologist based on individual risk factors and treatment duration.

Bicalutamide as an oral daily medication is generally less expensive than LHRH agonist depot injections, which require in-office administration every 1-6 months depending on formulation, though actual out-of-pocket cost depends heavily on insurance coverage for cancer treatment, which typically covers both options given their established use in prostate cancer care.

A single missed dose isn't typically a medical emergency given the medication's relatively long half-life, but consistent daily dosing matters for maintaining adequate androgen receptor blockade over time, so missed doses should be taken as soon as remembered (unless close to the next scheduled dose) and any pattern of missed doses discussed with the prescribing oncologist.

Yes — this transition happens when bicalutamide monotherapy alone becomes insufficient for cancer control, whether due to disease progression or simply as part of a planned treatment escalation, and switching between these approaches is a standard part of prostate cancer management discussed and adjusted with an oncologist as the disease picture evolves over time.

Generally less so — since bicalutamide preserves serum testosterone while LHRH agonists suppress it to castrate levels, and testosterone plays a protective role in bone density, bicalutamide monotherapy is associated with less bone loss risk than LHRH-based approaches, another quality-of-life advantage alongside its sexual function preservation benefit.

It's genuinely a shared decision — a patient can and should raise interest in bicalutamide monotherapy if it aligns with his priorities and disease stage, though the oncologist ultimately determines whether it's medically appropriate given the specific cancer characteristics, since it isn't suitable for every stage or risk category of prostate cancer.

Less frequently and less severely — since testosterone is preserved rather than suppressed to castrate levels, bicalutamide monotherapy causes hot flashes in a smaller proportion of men than LHRH agonists, another quality-of-life advantage of this approach.